Emergent BioSolutions, Inc. (NYSE: EBS) shares plunged Monday. The Gaithersburg, Md.-based company announced it made a voluntary prepayment of $100 million under its outstanding term loan facility in late December 2025 using cash on hand.
“This significant milestone reflects strong progress in improving our overall financial/cash position, enhancing our financial flexibility and positioning Emergent for long-term stability and growth,” stated CEO Joe Papa. “We continue to maintain a strong cash position for future strategic initiatives that are aligned with our mission, drive our turnaround plan and ultimately help deliver on our transformation efforts in 2026 and beyond.”
Since 2023, and now with this prepayment in effect, Emergent’s gross debt has been reduced by $275 million, to a total of $593 million (pro forma as of September 30, 2025). This represents a 32 percent decline in total debt since Emergent has undertaken its multi-year transformation plan.
“At Emergent,” according to this morning’s news release, “our mission is to protect and save lives. For over 25 years, we have prepared those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies.”
Shares in EBS kicked off Monday and the week down 63 cents, or 4.8%, at $12.34.
Related Stories
